Proposed Combination Product Rules Tackle GMPs, Adverse Events
This article was originally published in The Silver Sheet
TWO PROPOSED RULES FOR COMBO PRODUCT FIRMS focus on "streamlined" GMP and post-market surveillance requirements for manufacturers. FDA is also working on a companion guidance, which will be released when the combination product GMP rule is finalized
You may also be interested in...
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.